| Global Cancer Statistics 2022: the trends projection analysis BS Chhikara, K Parang Chemical Biology Letters 10 (1), 451-451, 2023 | 689 | 2023 |
| Self-assembly of peptides to nanostructures D Mandal, AN Shirazi, K Parang Organic & biomolecular chemistry 12 (22), 3544-3561, 2014 | 345 | 2014 |
| A global review on short peptides: frontiers and perspectives V Apostolopoulos, J Bojarska, TT Chai, S Elnagdy, K Kaczmarek, ... Molecules 26 (2), 430, 2021 | 343 | 2021 |
| Mechanism-based design of a protein kinase inhibitor K Parang, JH Till, AJ Ablooglu, RA Kohanski, SR Hubbard, PA Cole Nature structural biology 8 (1), 37-41, 2001 | 294 | 2001 |
| Protein pyrophosphorylation by inositol pyrophosphates is a posttranslational event R Bhandari, A Saiardi, Y Ahmadibeni, AM Snowman, AC Resnick, ... Proceedings of the National Academy of Sciences 104 (39), 15305-15310, 2007 | 249 | 2007 |
| Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity BJ Fowler, BD Gelfand, Y Kim, N Kerur, V Tarallo, Y Hirano, S Amarnath, ... Science 346 (6212), 1000-1003, 2014 | 245 | 2014 |
| Cell‐penetrating homochiral cyclic peptides as nuclear‐targeting molecular transporters D Mandal, A Nasrolahi Shirazi, K Parang Angewandte Chemie-International Edition 50 (41), 9633, 2011 | 230 | 2011 |
| Novel approaches for designing 5'-o-ester prodrugs of 3'-azido-2'3'-dideoxythymidine (AZT) K Parang, LI Wiebe, EE Knaus Current medicinal chemistry 7 (10), 995-1039, 2000 | 209 | 2000 |
| Impairment of TrkB-PSD-95 signaling in Angelman syndrome C Cao, MS Rioult-Pedotti, P Migani, CJ Yu, R Tiwari, K Parang, ... PLoS biology 11 (2), e1001478, 2013 | 193 | 2013 |
| Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease T Force, K Kuida, M Namchuk, K Parang, JM Kyriakis Circulation 109 (10), 1196-1205, 2004 | 165 | 2004 |
| Current targets for anticancer drug discovery NH Nam, K Parang Current drug targets 4 (2), 159-179, 2003 | 161 | 2003 |
| Designing bisubstrate analog inhibitors for protein kinases K Parang, PA Cole Pharmacology & therapeutics 93 (2-3), 145-157, 2002 | 152 | 2002 |
| Cyclic cell-penetrating peptides as efficient intracellular drug delivery tools SE Park, MI Sajid, K Parang, RK Tiwari Molecular pharmaceutics 16 (9), 3727-3743, 2019 | 142 | 2019 |
| Development of cytarabine prodrugs and delivery systems for leukemia treatment BS Chhikara, K Parang Expert opinion on drug delivery 7 (12), 1399-1414, 2010 | 141 | 2010 |
| Design and biological evaluation of cell-penetrating peptide–doxorubicin conjugates as prodrugs A Nasrolahi Shirazi, R Tiwari, BS Chhikara, D Mandal, K Parang Molecular pharmaceutics 10 (2), 488-499, 2013 | 139 | 2013 |
| Synthesis of 3-phenylpyrazolopyrimidine-1, 2, 3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities A Kumar, I Ahmad, BS Chhikara, R Tiwari, D Mandal, K Parang Bioorganic & medicinal chemistry letters 21 (5), 1342-1346, 2011 | 132 | 2011 |
| A review (research and patents) on jasmonic acid and its derivatives A Ghasemi Pirbalouti, SE Sajjadi, K Parang Archiv der Pharmazie 347 (4), 229-239, 2014 | 113 | 2014 |
| Fatty acyl amide derivatives of doxorubicin: Synthesis and in vitro anticancer activities BS Chhikara, NS Jean, D Mandal, A Kumar, K Parang European journal of medicinal chemistry 46 (6), 2037-2042, 2011 | 113 | 2011 |
| Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase S Lee, X Lin, NH Nam, K Parang, G Sun Proceedings of the National Academy of Sciences 100 (25), 14707-14712, 2003 | 102 | 2003 |
| Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate BS Chhikara, D Mandal, K Parang Journal of medicinal chemistry 55 (4), 1500-1510, 2012 | 100 | 2012 |